BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260521T190000
DTEND;TZID=Africa/Nairobi:20260521T203000
DTSTAMP:20260530T164021
CREATED:20260525T210458Z
LAST-MODIFIED:20260526T194356Z
UID:41677-1779390000-1779395400@kesho-kenya.org
SUMMARY:Bladder Cancer Care
DESCRIPTION:SPEAKERS: Dr. Patrick Mbuthia\, Dr. Helena Musau\, Dr Mohammed Ezzi\nDate: 21st May 2026\nModerator: Dr. Sitna Mwanzi \nThis session examined bladder cancer through a multidisciplinary lens\, bringing together surgical\, radiotherapeutic and systemic treatment perspectives across the continuum of care. \nA central theme was the need for accurate staging and risk-adapted management. Dr. Patrick Mbuthia discussed the role of transurethral resection of bladder tumour (TURBT) in diagnosis\, staging and treatment\, particularly for non-muscle invasive disease. The importance of complete resection\, adequate detrusor muscle in the specimen\, careful imaging and attention to complications was emphasized as central to subsequent treatment decisions. \nDr. Helena Musau highlighted the evolving role of radiotherapy in bladder preservation\, especially through tri-modality therapy combining maximal TURBT\, concurrent chemoradiation and structured response assessment. The discussion also addressed patient selection\, surveillance\, salvage options\, palliative radiotherapy for symptoms\, and the value of newer radiotherapy techniques in reducing toxicity while preserving quality of life. \nDr. Mohammed Ezzi reviewed systemic treatment across non-muscle invasive\, muscle invasive and metastatic bladder cancer. He outlined the role of intravesical therapy\, BCG\, cisplatin eligibility\, immunotherapy\, maintenance strategies and emerging options such as antibody-drug conjugates and targeted agents\, while noting that cost and availability continue to shape real-world treatment in Kenya. \nAcross the session\, a consistent message emerged: improving bladder cancer outcomes requires timely diagnosis\, high-quality TURBT\, multidisciplinary decision-making and treatment pathways that reflect both evidence and local access reality. \nKey Takeaways \n\nBladder cancer management depends on accurate staging and distinction between non-muscle invasive and muscle invasive disease.\nHigh-quality TURBT with adequate muscle sampling is central to diagnosis and treatment planning.\nTrimodality therapy offers bladder preservation for carefully selected patients.\nSystemic therapy is rapidly evolving with immunotherapy\, maintenance approaches and antibody-drug conjugates.\nLocal data are needed to address African patterns of disease\, including schistosomiasis-associated squamous cell carcinoma.\n\n 
URL:https://kesho-kenya.org/event/bladder-cancer-care/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/Bladder-Cancer-Care-e1779824625799.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260528T190000
DTEND;TZID=Africa/Nairobi:20260528T203000
DTSTAMP:20260530T164021
CREATED:20260525T190142Z
LAST-MODIFIED:20260529T182745Z
UID:41658-1779994800-1780000200@kesho-kenya.org
SUMMARY:The Brain Tumour Journey
DESCRIPTION:Speakers: Dr. Michael Magoha; Dr. Sarah Muma; Dr. Parmenas Minda Okemwa\nModerator: Mr. David L. Oluoch-Olunya \nThe Brain Tumour Journey brought together neurosurgery\, paediatric haemato-oncology and neuropathology perspectives to examine how multidisciplinary collaboration can improve care for patients with brain tumours. The session positioned brain tumour management as a continuum\, from first symptoms and referral to surgery\, pathology\, oncology treatment\, rehabilitation\, follow-up and family support. \nDr. Michael Magoha opened the session by reframing the brain tumour journey around the patient experience. He noted that brain tumours often carry fear and uncertainty\, yet they are not a single diagnosis or a uniform prognosis. With more than 150 tumour types and subtypes\, the patient’s pathway can vary widely. His presentation highlighted the role of patient navigation in helping individuals move through imaging\, surgery\, pathology\, endocrine review\, oncology care and long-term follow-up without being lost in fragmented systems. \nDr. Sarah Muma focused on the multidisciplinary management of childhood brain tumours in Kenya. She highlighted that brain and CNS tumours appear under-recognised in local and African childhood cancer data\, suggesting delays in diagnosis and referral. Children may present with persistent headaches\, vomiting\, visual changes\, seizures\, gait or coordination problems\, abnormal head growth\, behavioral changes or endocrine-related symptoms. The discussion emphasized the need for a higher index of suspicion\, especially when symptoms are progressive\, recurrent or not responding as expected. \nThe session also examined Kenyan system-level challenges\, including limited access to timely imaging\, prolonged pathways between surgery and radiotherapy\, scarcity of formal paediatric neuro-oncology programs and treatment abandonment. Dr. Muma described the value of neuro-oncology multidisciplinary clinics\, where patients and families can receive coordinated input from neurosurgery\, oncology\, radiology\, pathology\, rehabilitation\, counselling and navigation teams within a more structured care pathway. \nDr. Parmenas Minda Okemwa closed the presentations by discussing the principles and diagnostic challenges of brain tumour pathology. He emphasized that pathology remains the gold standard for diagnosis\, but modern brain tumour care increasingly depends on integrated reporting that combines clinical context\, radiology\, histology\, immunohistochemistry and molecular testing. His presentation underscored the need for adequate tissue sampling\, stronger neuropathology capacity\, expanded diagnostic panels\, molecular testing access and regular multidisciplinary tumour board discussions. \nAcross the session\, the message was clear: improving brain tumour outcomes requires coordinated systems\, not isolated excellence. Timely diagnosis\, accurate pathology\, surgical expertise\, oncology planning\, patient navigation\, rehabilitation and survivorship support must work together if patients are to receive care that is clinically sound\, humane and sustainable. \nKey Takeaways\n\nBrain tumour care is a journey\, not a single event. Patients often require coordinated input across imaging\, surgery\, pathology\, oncology treatment\, rehabilitation and follow-up.\nPatient navigation can reduce fragmentation. Navigators help patients and families move through complex health systems and reduce the risk of missed appointments\, delayed reviews or incomplete follow-up.\nChildren may present with subtle or progressive symptoms. Persistent headaches\, seizures\, visual changes\, gait problems\, behavioural changes or endocrine symptoms should prompt a high index of suspicion.\nMultidisciplinary clinics can shorten delays. Same-day or coordinated review by several specialists can improve treatment planning and reduce the burden on families.\nAccurate diagnosis depends on integrated pathology. Histology remains central\, but immunohistochemistry and molecular testing increasingly guide classification\, prognosis and treatment options.\nKenya’s neuro-oncology systems are advancing but need strengthening. Referral pathways\, registries\, specialist training\, diagnostic capacity\, molecular testing access and survivorship systems remain key priorities.
URL:https://kesho-kenya.org/event/advancing-care-through-multidisciplinary-collaboration/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/05/WhatsApp-Image-2026-05-28-at-3.56.29-PM-1-e1780079236823.jpeg
END:VEVENT
END:VCALENDAR